Last reviewed · How we verify
NCT07145359
Virtual Reality Intervention for Symptom Management in Stem Cell Transplantation
NA trial testing Virtual Reality Intervention in Cancer and / or Hematological Malignancy in 30 participants. Not yet recruiting.
10 June 2026
Quick facts
| Lead sponsor | Halic University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 10 September 2025 |
| Primary completion | 10 June 2026 |
| Estimated completion | 10 September 2026 |
Drugs / interventions tested
- Virtual Reality Intervention
Conditions studied
- Cancer and / or Hematological Malignancy — all drugs for Cancer and / or Hematological Malignancy →
- Hematopoetic Stem Cell Transplantation — all drugs for Hematopoetic Stem Cell Transplantation →
- Nursing Interventions — all drugs for Nursing Interventions →
- Symptom Management — all drugs for Symptom Management →
Sponsor
Halic University
Who can join
18 and older, any sex, with Cancer and / or Hematological Malignancy or Hematopoetic Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate whether a virtual reality (VR) intervention based on the Symptom Management Model can reduce physical and psychosocial symptoms during hematopoietic stem cell transplantation (HSCT) in adult patients undergoing allogeneic transplantation. The main questions it aims to answer are: Does the VR intervention reduce distress levels during HSCT? Does the VR intervention decrease state anxiety and symptom severity compared to standard care? Does the VR intervention positively affect physiological outcomes and engraftment times? Researchers will compare a group receiving standard clinical care plus a VR nature-themed video during HSCT to a group receiving standard care only to see if the VR intervention improves symptom management outcomes. Participants will: Be randomly assigned to either the intervention or control group. In the intervention group: Watch a 15-minute nature-themed VR video during stem cell infusion using Meta Quest 3. The video content will be specifically created by the research team based on the principles of Attention Restoration Theory (ART). In both groups: Complete pre- and post-intervention assessments including: Distress Thermometer State-Trait Anxiety Inventory Edmonton Symptom Assessment Scale Physiological measures (vital signs) Engraftment tracking Satisfaction and open-ended feedback forms
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07145359
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Virtual Reality Intervention
Trials testing the same drug.
- NCT07082790 — Effect of VR and Music on Fetal Well-Being and Anxiety During Nonstress Test · NA · completed
- NCT03605368 — VR Intervention to Improve Police Safety · NA · completed
Other Halic University trials
Trials by the same sponsor.
- NCT07424521 — Psychosocial Effects of Mindfulness-Based Exercise in Postmenopausal Women · NA · not yet recruiting
- NCT07425223 — Acute Effects of Kinesiology Taping on Performance in Volleyball Players · NA · not yet recruiting
- NCT07421583 — Acute Effects of Kinesiology Taping on Performance in Soccer Players · NA · not yet recruiting
- NCT07394439 — Respiratory Function, Respiratory Muscle Strength, and Hand Function in Hemiparetic Cerebral Palsy · not yet recruiting
- NCT07304180 — Exergame vs Balance Training in Hemiplegia · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07145359 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Halic University
- Last refreshed: 28 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07145359.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing